The biosimilar company, which has a $419M market capitalization, operates in Taiwan and Wuhan, China.
December 21, 2017 -- JHL Biotech is planning a voluntary delisting from the Taiwan stock exchange. The biosimilar company, which has a $419 million market capitalization, operates in Taiwan and Wuhan, China. The proposed delisting allows shareholders to hold on to their shares while the company is private, if they choose to do so. Following the delisting, JHL anticipates new sources of funding, most likely including an IPO on a foreign exchange. In 2012, JHL was founded in Taiwan by veterans of Genentech and Amgen with the goal of producing affordable, effective biosimilar drugs.
